Overcoming Drug Resistance in Gynecologic Cancers

Volume 17
Erscheinungsjahr 2021
ISBN: 978-0-12-824299-5
Verlag: Elsevier Science

Buch, Englisch, 388 Seiten, Format (B × H): 191 mm x 235 mm, Gewicht: 950 g

Overcoming Drug Resistance in Gynecologic Cancers provides up-to-date information related to important gynecologic cancers and focuses on mechanisms of drug resistance, genetics, signaling, immunology, health disparities, nanotechnology, economic considerations and financial impacts. The book covers not only drug resistance but also important means to reverse resistance both in the laboratory and clinic. The book discusses topics such as lifestyle, nutrition and risk of gynecologic cancers, the financial impact of drug resistance, chemosensitizing agents and targeted therapies in cervical, endometrial and ovarian cancer, immunotherapy to overcome drug resistance, and genetic polymorphisms in gynecologic cancers.

Additionally, it discusses ethnic and racial health disparity perspectives and future developments in chemosensitizing activities to reverse drug resistance in gynecologic cancers. It is a valuable resource for cancer researchers, oncologists, clinicians and other biomedical field members who are interested in new approaches to improve chemotherapy outcome in patients with gynecologic cancers.

Zielgruppe

<p>Cancer researchers, medical scientists, clinicians, graduate students</p>

Autoren/Hrsg.

Weitere Mitwirkende

Ahmad, Sarfraz

Fachgebiete

• Naturwissenschaften Biowissenschaften Biowissenschaften

Inhaltsverzeichnis

1. Introduction to gynecologic cancers: An emphasis on pathogenesis, incidence sand diagnosis

2. Lifestyle, nutrition, and risk of gynecologic cancers

3. Drug Resistance in Gynecologic Cancers: Findings and Underlying Mechanisms

4. Mechanisms of Chemo-resistance and Approaches to Overcome its Impact in Gynecologic Cancers

5. Drug resistance in gynecologic cancers: Findings and underlying mechanismsCurrent Treatment Modalities in Major Gynecologic Cancers: Emphasis on Response Rates

6. Drug Resistance in Gynecologic Cancers: Emphasis on Non-coding RNAs and Drug Efflux Mechanisms

7. Genetic Polymorphisms in Gynecologic Cancers

8. Overcoming Drug Resistance in Cervical Cancer: Chemo-sensitizing Agents and Targeted Therapies

9. Immune Response, Inflammation Pathway Gene Polymorphisms and the Risk of Cervical Cancer

10. Overcoming Chemotherapy Resistance in Endometrial Cancer

11. Chemoresistance in Uterine Cancer: Mechanisms of Resistance and Current Therapies

12. Ovarian Cancer: Targeted Therapies and Mechanisms of Resistance

13. Overcoming Drug Resistance in Ovarian Cancer: Chemo-sensitizing Agents, Targeted Therapies

14. Resistance to Chemotherapy Among Ethnic and Racial Groups: Health Disparities Perspective in Gynecologic Cancers

15. Future Perspectives and New Directions in Chemosensitizing Activities to Reverse Drug Resistance in Gynecologic Cancers: Emphasis on Challenges and Opportunities

Über Autor(innen)

Ahmad, Sarfraz
Prof. Sarfraz Ahmad is Director of Clinical Research at Gynecologic Oncology Program of AdventHealth Cancer Institute (AHCI), Orlando, FL, USA. He earned his PhD in Biochemistry from North-Eastern Hill University, Shillong. Prof. Ahmad's research focus is on the analyses of clinico-pathologic and surgical outcomes of oncology, hematology, and gastroenterology patients and to better understand the cellular/molecular mechanisms of cancer and related thromboembolic/hematologic disorders. Prof. Ahmad has published over 275 peer-reviewed scholarly research articles and book chapters, and over 400 scientific abstracts. He is a reviewer and has editorial responsibilities for several biomedical journals and books; and has received competitive research grants and national/international awards for his research contributions/accomplishments